Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Dundee’s Exscientia signs $25m drug deal

Exscientia chief executive Andrew Hopkins
Exscientia chief executive Andrew Hopkins

Dundee-based life sciences firm Exscientia has received an upfront payment of $25 million to enter a new partnership with a global pharmaceutical firm.

The Dundee University spin-out announced it had entered a three year collaboration with NASDAQ-listed American biotech Celgene.

Exscientia is a world leader at using artificial intelligence (AI) to automate drug design, which speeds up the development of drug candidates.

As well as the bumper initial payment, Exscientia will receive further payments based on the success of the programme.

The firm — which was recently valued at £100m — will also receive tiered royalties on any product resulting from the tie-up.

Exscientia chief executive Professor Andrew Hopkins said: “We’re incredibly proud to collaborate with Celgene and to sign another partnership with a key industry player, reinforcing our place at the forefront of AI drug discovery.

“Today, patients can wait more than 10 years from initial drug discovery to its availability as a treatment.

“With autoimmune diseases and cancer rates increasing, the pharmaceutical industry’s R&D productivity needs to dramatically improve – and technology is a key part of this.”

The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in the areas of oncology and autoimmunity.

Exscientia’s systems learn from existing data resources and experimental data.

The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends.

Exscientia, which has its headquarters in Oxford, claims its drug discovery platform reduces the time required to discover pre-clinical drug candidates by 75%.

“AI combined with human creativity can significantly accelerate the drug discovery process and thus drastically improve access of new drugs to the market,” Mr Hopkins added.

The deal extends Exscientia’s list of partnerships with blue chip pharma and biotech companies, with existing collaborations involving Roche, GSK, Sanofi and Evotec.

At the start of this year, Exscientia secured a $26m Series B investment to expand its capabilities, develop its platform and build its proprietary drug pipeline.

rmclaren@thecourier.co.uk